Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Research in CMAJ Open

Highlights

CMAJ December 06, 2016 188 (17-18) 1229; DOI: https://doi.org/10.1503/cmaj.161338
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

Speed of hormonal contraceptive approval

This study compared approval times for new hormonal contraceptives by Health Canada, the US Food and Drug Administration (FDA), and the UK Medicines and Healthcare Products Regulatory Agency (MHRA) from 2000 to 2015, using public data sources and direct correspondence with the regulatory bodies. During the study period, 16 contraceptives were approved in Canada, 26 in the US and 14 in the UK. Applications for novel contraceptives were initiated later in Canada, and time to approval was longer in Canada than in the US (p = 0.03). Once an application was submitted, Health Canada tended to require 30% more time to approve contraceptives than the FDA in the US, and nearly 50% more time than the MHRA in the UK (Figure 1). The median time to approval for all hormonal contraceptives in Canada was 529.5 (interquartile range [IQR] 420.8–784.0) days, compared with 396.0 (IQR 308.0–594.5) days in the US and 341.0 (IQR 244.8–512.2) days in the UK. In contrast to the US and UK, no subdermal implant contraceptives were approved in Canada, although the authors note that the active drugs in these products are approved for use in other delivery systems. Canadian women wait longer for novel contraceptive methods and have fewer options than women in the US and UK, say the authors. CMAJ Open 2016;4:E654–60.

Figure 1:
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1:

Distribution of time to approval for hormonal contraceptives, 2000–2015, by country. The squares indicate approval times for each drug, and the dashed lines indicate the medians.

Colistin resistance in Canada

Colistin is often used as an antimicrobial of last resort for treating infections caused by multidrug-resistant gram-negative bacilli. In 2015, plasmid-mediated colistin resistance due to MCR-1 was described in Escherichia coli. This study evaluated the frequency of colistin resistance among E. coli clinical isolates obtained from patients in Canadian hospitals as part of the Canadian Ward Surveillance Study and determined how often the mcr-1 gene was detected among the colistin-resistant subset, using polymerase chain reaction. From 2008 to 2015 (excluding 2011), 10 to 15 sentinel hospitals submitted consecutive clinical isolates (1 per patient per infection site) from blood (100–240), respiratory (100–150), urine (25–100) and wound (25–100) infections each year. Of the 5571 E. coli clinical isolates obtained during the study period, only 12 isolates (0.2%) were resistant to colistin. The proportion of colistin-resistant isolates varied annually from 0.0% to 0.5% depending on the study year (Table 1). There was no clear trend toward increasing resistance over time. Typically, the colistin-resistant isolates remained susceptible to antimicrobials from several other classes. Two colistin-resistant isolates (0.04%) were found to harbour the mcr-1 gene. These results suggest that colistin resistance among E. coli human clinical isolates, including resistance mediated by the mcr-1 gene, remains rare in Canada. CMAJ Open 2016;4:E641–5.

View this table:
  • View inline
  • View popup
Table 1:

Susceptibility of Escherichia coli clinical isolates to colistin, stratified by study year

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 188 (17-18)
CMAJ
Vol. 188, Issue 17-18
6 Dec 2016
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Highlights
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Highlights
CMAJ Dec 2016, 188 (17-18) 1229; DOI: 10.1503/cmaj.161338

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Highlights
CMAJ Dec 2016, 188 (17-18) 1229; DOI: 10.1503/cmaj.161338
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Speed of hormonal contraceptive approval
    • Colistin resistance in Canada
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Highlights
  • Highlights
Show more Research in CMAJ Open

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire